Randomized trial shows no significant link between alpha-1 antitrypsin genotype and COPD exacerbations in lung disease patients, suggesting further exploration is needed.
Key Points
The aim is to evaluate the association between alpha-1 antitrypsin carrier genotypes and the risk of COPD exacerbations.
Ongoing study enrolling patients with confirmed spirometry obstruction from University of Florida - Jacksonville.
Collected demographic data, alpha-1 genotype, protein levels, and number of COPD exacerbations.
Chi-square test and odds ratios calculated to assess genotype-exacerbation relationship.
Exacerbations occurred in 52.6% of patients with PiMM genotype and 50% in heterozygous individuals.
No statistically significant association found between alpha-1 genotype and exacerbation status (p = 0.93).
Odds ratio for heterozygous group was 1.11 (95% CI 0.45-2.71), indicating no significant risk increase.